|05/23/17||Pacira Pharmaceuticals Announces Resignation of James Scibetta|
|PARSIPPANY, N.J., May 23, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that James Scibetta is resigning as the company’s president to become chief executive officer of an undisclosed private early-stage oncology company. Pacira will allocate Mr. Scibetta’s operational oversight responsibilities to the current leadership team and does not intend to name a successor. Mr. Scibetta will remain with the company through June 30 to ensure a seamless transition p... |
|05/10/17||Pacira Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference|
|PARSIPPANY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 8:00 AM PT on Wednesday, May 17, 2017 in Las Vegas.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on ... |
|05/04/17||Pacira Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results|
|-- EXPAREL® Net Product Sales Up 6% Year-Over-Year --
-- Conference Call Today at 8:30 a.m. ET --
PARSIPPANY, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2017.
“We’re pleased with our strong first quarter highlighted by important strategic advances a... |
|05/03/17||New Research Shows Vast Majority of Oral Surgery Patients Would Choose Non-opioid Medication to Treat Postsurgical Pain if Given the Option|
|Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction
PARSIPPANY, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- According to a new national survey of over 1,500 oral surgery patients or their parents, more than seven in 10 respondents indicated they would opt for a non-opioid medication to treat postsurgical pain from third molar (wisdom tooth) extraction if given the choice. Approximately 80 percent... |